Xiamen Amoytop Biotech Co., Ltd.

Shanghai Stock Exchange 688278.SS

Xiamen Amoytop Biotech Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: 29.60%

Xiamen Amoytop Biotech Co., Ltd. Return on Equity (ROE) is 29.60% for the year ending December 31, 2023, a 45.17% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Xiamen Amoytop Biotech Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was 20.39%, a 30.68% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 15.60%, a 33.91% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 11.65%, a 2.14% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 11.41%, a 255.93% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shanghai Stock Exchange: 688278.SS

Xiamen Amoytop Biotech Co., Ltd.

CEO	Mr. Li Sun
IPO Date	Jan. 17, 2020
Location	China
Headquarters	No. 330 Wengjiao Road
Employees	1,960
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Cleaning Supplies Composite Materials Fertilizers Petrochemicals Pharmaceuticals Plastics

Description

Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.

Key trends

Past 5 years